However, more studies are required to determine the exact mechanism of the involvement of the PI3K/AKT and ERK1/2 pathways in regulation of ADAM10 expression and investigate them as a therapeutic target in AD (Figs. 1, 2). This evidence concerns the gene MAPK3 and Alzheimer disease.